Survodutide Dosage Guide
50/100 confidenceComplete guide to Survodutide dosing protocols, administration methods, and safety considerations for research purposes.
Dosage Overview
Dose per Injection
2.4 mg – 6 mg
Frequency
Once per week
Route
subcutaneous
Detailed Dosage Information
Phase 2 MASH trial
escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly.
Phase 2b obesity trial
up to 6.0 mg weekly.
Dose escalation over 16-20 weeks to manage GI tolerability.
Final approved dosing not yet established — Phase 3 trials ongoing.
Administration Method
Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027.
Research Backing
Phase 2 MASH trial: up to 87% MASH resolution at 48 weeks (6 mg). Phase 2b obesity trial: up to 18.7% weight loss at 46 weeks. Phase 3 SYNCHRONIZE (MASH) and ACHIEVE (obesity) programs ongoing.
Side Effects to Monitor
Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists.
Safety Considerations & Risks
Pre-approval medication — full safety profile not yet established. Glucagon receptor activation may transiently increase hepatic glucose output (theoretical concern for diabetic patients). Thyroid C-cell tumor risk not yet fully assessed. No long-term safety data beyond 48 weeks.